- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- aspirin
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15,076 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 40
- States / cities
- Los Angeles, California • Wilmington, Delaware • Gainesville, Florida + 28 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–16
of 16
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Pemetrexed, Cisplatin, Necitumumab
- Drug · Biological
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 633 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2020
- U.S. locations
- 1
- States / cities
- Nyack, New York
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Necitumumab, Gemcitabine, Cisplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Sacramento, California + 12 more
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 4
- States / cities
- Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York + 1 more
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- lifestyle modification instructional and motivational sessions
- Behavioral
- Lead sponsor
- Medidata Solutions
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Sensorimotor Gait Disorder, Neurologic Ambulation Disorder, Gait, Drop Foot, Poststroke Hemiparesis, Post-Cerebrovascular Accident (CVA) Hemiparesis
- Interventions
- Ness L300, Ankle-foot orthosis
- Device
- Lead sponsor
- Bioness Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 197 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 11
- States / cities
- Downey, California • Long Beach, California • San Diego, California + 8 more
- Conditions
- Solid Tumor
- Interventions
- Durvalumab
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 12
- States / cities
- Fullerton, California • Washington D.C., District of Columbia • Augusta, Georgia + 9 more
- Conditions
- Erosive Esophagitis
- Interventions
- Nexium 20mg, Nexium 10mg
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 1 Year to 11 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • Sacramento, California • Miami, Florida + 7 more
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102, Vehicle
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 302 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 17
- States / cities
- Miami, Florida • Saint Augustine, Florida • Meridian, Idaho + 13 more
- Conditions
- Congenital Heart Disease With Fontan Circulation
- Interventions
- macitentan 10 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Spokane, Washington
- Conditions
- Common Warts (Verruca Vulgaris), Common Warts, Human Papilloma Virus (HPV), Warts
- Interventions
- Cantharidin
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 10
- States / cities
- Saint Augustine, Florida • Plainfield, Indiana • New Orleans, Louisiana + 7 more
- Conditions
- Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
- Interventions
- macitentan 10 mg
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 11
- States / cities
- Littleton, Colorado • Chicago, Illinois • Iowa City, Iowa + 8 more
- Conditions
- Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
- Interventions
- VP-102 (US) / TO-208 (Japan), Vehicle (US) / Vehicle (Japan)
- Combination Product
- Lead sponsor
- Verrica Pharmaceuticals Inc.
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 12
- States / cities
- San Diego, California • Jacksonville, Florida • Sweetwater, Florida + 9 more
- Conditions
- Cystic Fibrosis
- Interventions
- Cavosonstat, Placebo
- Drug
- Lead sponsor
- Nivalis Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
- Conditions
- Chronic Kidney Disease + Hyperkalaemia +/- Heart Failure
- Interventions
- Calcium Polystyrene Sulphonate 15g/60 mL water, Lokelma® 5 g/45mL water, Lokelma® 10 g/45 mL water, Veltassa® 8,4 g/80mL water, Sodium Polystyrene Sulphonate 15g/60 mL water
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 130 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Temple Terrace, Florida • West Palm Beach, Florida
- Conditions
- Carotid Artery Stenosis, Carotid Artery Diseases, Carotid Stenosis
- Interventions
- Carotid artery stenting with Neuroguard IEP System
- Device
- Lead sponsor
- Contego Medical, Inc.
- Industry
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 28
- States / cities
- Huntsville, Alabama • St. Helena, California • Washington D.C., District of Columbia + 24 more